Scancell Holdings logo

SCLP - Scancell Holdings Share Price

22.9p 0.0  0.0%

Last Trade - 09/04/21

Small Cap
Market Cap £181.3m
Enterprise Value £159.1m
Revenue £n/a
Position in Universe 864th / 1817
Unlock SCLP Revenue
Relative Strength (%)
1m -7.47%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -21.0%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Apr 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000
Balance Sheet
FINANCIAL BRIEF: : For the six months ended 31 October 2020, ScancellHoldings Plc revenues was not reported. Net loss increased54% to £3.9M. Higher net loss reflects Interest receivableand similar income decrease of 75% to £2K (income). BasicEarnings per Share excluding Extraordinary Items remainedflat at -£0.01.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for SCLP
Graphical History


SCLP Revenue Unlock SCLP Revenue

Net Income

SCLP Net Income Unlock SCLP Revenue

Normalised EPS

SCLP Normalised EPS Unlock SCLP Revenue

PE Ratio Range

SCLP PE Ratio Range Unlock SCLP Revenue

Dividend Yield Range

SCLP Dividend Yield Range Unlock SCLP Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
SCLP EPS Forecasts Unlock SCLP Revenue
Profile Summary

Scancell Holdings plc is a biopharmaceutical company focused on the cancer therapeutics market. The Company's principal activity consists of the discovery and development of monoclonal antibodies and vaccines for the treatment of cancer. The Company is developing a pipeline of immunotherapies for the treatment of cancer based on its ImmunoBody and Moditope platforms. The Company's products include SCIB1, SCIB2 and Modi-1. The Company's first cancer vaccine, SCIB1, is being developed for the treatment of melanoma and is in Phase I/II clinical trials. SCIB2 contains multiple T cell epitopes derived from the lung cancer associated antigen NY-ESO-1. It is developed to the point at which the product is defined and ready for further preclinical development as an immunotherapy for any tumor that expresses the NY-ESO-1 antigen. The Company's first Moditope development candidate is Modi-1. Modi-1 consists of two citrullinated vimentin peptides and one citrullinated enolase peptide.

Last Annual April 30th, 2020
Last Interim October 31st, 2020
Incorporated April 14, 2008
Public Since July 30, 2010
No. of Shareholders: n/a
No. of Employees: 22
Sector Healthcare
Industry Biotechnology & Medical Research
Index FTSE Aim All Share ,
Exchange London Stock Exchange (AIM)
Shares in Issue 791,917,828
Free Float (0.0%)
Eligible for
SCLP Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for SCLP
Upcoming Events for SCLP
Frequently Asked Questions for Scancell Holdings
What is the Scancell Holdings share price?

As of 09/04/21, shares in Scancell Holdings are trading at 22.9p, giving the company a market capitalisation of £181.3m. This share price information is delayed by 15 minutes.

How has the Scancell Holdings share price performed this year?

Shares in Scancell Holdings are currently trading at 22.9p and the price has moved by 0.359k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Scancell Holdings price has moved by 0.271k% over the past year.

What are the analyst and broker recommendations for Scancell Holdings?

Of the analysts with advisory recommendations for Scancell Holdings, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Scancell Holdings is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Scancell Holdings next release its financial results?

Scancell Holdings is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-10-31
What is the Scancell Holdings dividend yield?

Scancell Holdings does not currently pay a dividend.

Does Scancell Holdings pay a dividend?

Scancell Holdings does not currently pay a dividend.

When does Scancell Holdings next pay dividends?

Scancell Holdings does not currently pay a dividend.

How do I buy Scancell Holdings shares?

To buy shares in Scancell Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Scancell Holdings?

Shares in Scancell Holdings are currently trading at 22.9p, giving the company a market capitalisation of £181.3m.

Where are Scancell Holdings shares listed? Where are Scancell Holdings shares listed?

Here are the trading details for Scancell Holdings:

Country of listing: United Kingdom
Exchange: LSE
Ticker Symbol: SCLP
What kind of share is Scancell Holdings?

Based on an overall assessment of its quality, value and momentum, Scancell Holdings is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Scancell Holdings share price forecast 2021?

Shares in Scancell Holdings are currently priced at 22.9p. At that level they are trading at 19.65% premium to the analyst consensus target price of 19.14.

Analysts covering Scancell Holdings currently have a consensus Earnings Per Share (EPS) forecast of -0.0135 for the next financial year.

How can I tell whether the Scancell Holdings share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Scancell Holdings. Over the past six months, the relative strength of its shares against the market has been 23.04%. At the current price of 22.9p, shares in Scancell Holdings are trading at 63.95% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Scancell Holdings PE Ratio?

We were not able to find PE ratio data for Scancell Holdings.

Who are the key directors of Scancell Holdings?

Scancell Holdings's management team is headed by:

Lindy Durrant - CSO
Richard Goodfellow - EDR
Sally Adams - OTH
John Chiplin - NEC
Clifford Holloway - CEO
Martin Diggle - NED
Ursula Ney - NED
Susan Clement-Davies - NED
Gillies O'Bryan-Tear - OTH
Robert Miller - OTH
Who are the major shareholders of Scancell Holdings?

Here are the top five shareholders of Scancell Holdings based on the size of their shareholding:

Redmile Group, LLC Investment Advisor/Hedge Fund
Percentage owned: 29.11% (237.3m shares)
Vulpes Investment Management Private Limited Hedge Fund
Percentage owned: 14.25% (116.2m shares)
Calculus Capital Limited Private Equity
Percentage owned: 5.99% (48.8m shares)
Durrant (Lindy Gillian) Individual Investor
Percentage owned: 1.28% (10.4m shares)
Wood (Sir Martin Francis) Individual Investor
Percentage owned: 1.21% (9.85m shares)
Similar to SCLP
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.